HOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4 Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile and promising clinical activity In a subset of patients with PD-L1 combined positive score (CPS) of 20 or higher, data showed confirmed objective response rate (ORR) of 53%, complete response (CR) rate of 18%, and disease control rate (DCR) of 82% Company will also present promising preliminary progression-free ...